• Profile
Close

Can a combination immune therapy reduce genital herpes outbreaks?

MedicalXpress Breaking News-and-Events Aug 04, 2019

Yale investigators have shown that the combination of a vaccine and a medicated cream is a promising strategy to dramatically reduce the recurrence of genital herpes. Their study, co-led by researchers at the University of Pennsylvania and University of Cincinnati Children's Hospital Medical Center, was published in the journal npj Vaccines.

Herpes simplex virus (HSV) type 2, which causes genital herpes, is very common, affecting more than 400 million people worldwide. There's no cure and efforts to develop a vaccine have had limited success.

The research team tested a novel vaccine strategy, known as prime and pull, in guinea pigs infected with genital herpes. The "prime" involves a vaccine that generates a response to the virus from T cells, highly specialized immune cells. The "pull" consists of a cream containing imiquimod, a medication commonly used to treat genital warts. Applied to the affected area, the cream attracts key immune cells to the site of infection where they can block the virus from spreading and causing herpes lesions.

The study showed that the effect of the combination therapy was far greater than either the vaccine or cream alone. "It's the first time that a study has shown that prime-and-pull strategy can block existing recurrent disease," said co-corresponding author Akiko Iwasaki, the Waldemar Von Zedtwitz professor of immunobiology at Yale School of Medicine.

"Development of a therapeutic HSV vaccine is a high priority. Our exciting results have encouraged us and, hopefully others, to pursue this strategy with more vaccines," said co-corresponding author David Bernstein, professor of pediatrics and former director of the Division of Infectious Diseases at Cincinnati Children's Hospital.

The study team gave three rounds of treatment to the animals, noting that the strategy worked rapidly and beginning with the first round.

This strategy, if developed into a therapy for humans, could be a game changer for individuals with recurrent infections or resistance to standard antiviral treatment, said Iwasaki. Active herpes infection causes painful lesions that are physically and emotionally harmful to affected people, she noted.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay